Our results demonstrated that NIMA-related kinase 2 (Nek2) binds β-catenin, blocking the interaction between this protein and the destruction complex, and ultimately contributing to sorafenib resistance for HCC. Here, NEK2 is linked to hepatocellular carcinoma.